Welcome to our dedicated page for CeriBell SEC filings (Ticker: CBLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CeriBell, Inc. (Nasdaq: CBLL) SEC filings page on Stock Titan provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. As a medical technology company focused on point-of-care electroencephalography (EEG) for serious neurological conditions, CeriBell uses its filings to report financial performance, material agreements, intellectual property actions, and key product milestones related to the Ceribell System.
Investors can review periodic reports and current reports on Form 8-K that describe quarterly financial results, including separate disclosure of product revenue and subscription revenue, as well as updates on cash, marketable securities, and operating expenses. Filings also cover material definitive agreements, such as the Exclusive (Equity) Agreement with The Board of Trustees of the Leland Stanford Junior University for patent rights related to portable brain wave devices, and the Corporate Supply Agreement with Shenzhen Everwin Precision Technology Co., Ltd. and affiliates for EEG headband supply and related licenses.
Other 8-K filings document regulatory and legal developments, including announcements of FDA 510(k) clearance for the Clarity® algorithm in neonatal seizure detection, clearance for the company’s delirium monitoring solution, and the FDA Breakthrough Device Designation for its Large Vessel Occlusion (LVO) stroke detection monitor. Filings also describe patent infringement complaints filed against Natus Medical Incorporated and related subsidiaries, as well as lease amendments for office space in Sunnyvale, California and governance changes such as the election of new directors.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand financial trends, material contracts, regulatory events, and intellectual property issues affecting CBLL. Users can also track insider-related disclosures when available through forms such as Form 4, and refer to annual reports on Form 10-K and quarterly reports on Form 10-Q for deeper insight into CeriBell’s business, risk factors, and operations.
CBLL reported proposed resale transactions under a Form 144. The filing lists securities to be sold on 04/01/2026 arising from option grants dated 07/07/2021 (1,472 shares) and 02/16/2023 (9,640 shares). The filing also records prior open-market sales by Raymond Woo: 01/02/2026 (11,112 shares for $235,228.09), 02/02/2026 (11,112 shares for $228,408.70), 03/02/2026 (11,112 shares for $202,831.12), and 02/23/2026 (705 shares for $13,955.12). The broker on the notice is Fidelity Brokerage Services LLC.
Ceribell, Inc. President and CEO Chao Xingjuan reported exercising stock options to acquire a total of 55,628 shares of common stock. She exercised options for 36,628 shares at an exercise price of $2.24 per share and 19,000 shares at $3.65 per share.
After these transactions, she holds 766,792 shares of common stock directly. An additional 369,088 shares are held indirectly by the ACP 2021 Trust, where she is a co-trustee and may be deemed to share beneficial ownership, while disclaiming beneficial ownership except to the extent of her pecuniary interest.
Ceribell, Inc. Senior VP, Finance and PAO David Foehr exercised stock options and sold shares in the company. On March 3, 2026, he exercised options for 3,403 and 1,157 shares of common stock at $4.70 per share and then sold the same totals, 4,560 shares of common stock, at $17.80 per share in open-market transactions. After these trades, he directly held 17,550 shares of Ceribell common stock. The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025, and the underlying options vest over time through monthly installments after an initial 25% vesting on May 31, 2023.
Ceribell, Inc. director Rebecca B. Robertson reported an open-market sale of 827 shares of common stock at $17.80 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, and she now holds 18,749 shares directly.
Ceribell, Inc. President and CEO Xingjuan Chao exercised stock options and sold shares in a planned series of trades. She exercised options covering 1,446 and 23,554 shares of common stock at an exercise price of $4.70 per share, then sold a total of 39,000 common shares in open-market transactions on March 3, 2026 at weighted average prices around $17.45–$17.46 per share under a Rule 10b5-1 trading plan. Following these transactions, she holds 711,164 shares directly and has indirect exposure to 369,088 additional shares held by the ACP 2021 Trust, where she is a co-trustee and disclaims beneficial ownership beyond her pecuniary interest.
Ceribell, Inc. Chief Technology Officer Raymond Woo reported a set of option exercises and related share sales in Ceribell stock. On March 2, 2026, he exercised multiple stock options to acquire common shares and then sold 11,112 shares of common stock in open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on May 28, 2025. The reported sale prices were based on weighted-average prices within ranges from $18.10 to $18.41 per share. After these transactions, Woo directly held 166,912 shares of Ceribell common stock.
CBLL reports Form 144 notice of affiliate sales. The filing lists multiple sales by Xingjuan Chao, including 25,000 shares on 12/04/2025 for 470,532.50, 79,000 shares on 01/05/2026 for 1,680,124.43, 39,000 shares on 02/04/2026 for 786,392.36, and 2,084 shares on 02/23/2026 for 41,251.74.
The form also lists planned option-related sales and grants with dates and share counts, including 9,821 shares (09/25/2024), 4,179 shares (05/15/2025), and 25,000 shares (03/03/2026).
CBLL filed a Rule 144 resale notice listing 4,560 shares of common stock to be sold on 03/03/2026. The filing also lists recent officer sales by David J. Foehr, including 5,265 shares on 12/03/2025 for $88,609.95, 5,556 shares on 01/05/2026 for $125,565.60, 5,556 shares on 02/03/2026 for $111,120.00, 569 shares on 02/23/2026 for $11,263.07, and 781 shares on 02/24/2026 for $15,604.38.
Rebecca B. Robertson reported sales of common stock on a Form 144. The record shows a sale of 5,000 shares on 12/08/2025 for $100,000 and a sale of 2,500 shares on 01/02/2026 for $54,725.
The filing also lists 827 shares associated with restricted stock vesting on 03/01/2026 and shows Fidelity Brokerage Services LLC as a broker of record.
Raymond Woo filed a Form 144 reporting proposed and recent sales of Common stock. The notice lists proposed sales of 9,640 and 1,472 shares dated 03/02/2026, and reports recent sales of 11,112 shares on 01/02/2026, 11,112 shares on 02/02/2026, and 705 shares on 02/23/2026. The entries include cash amounts tied to those past sales.